A Mid-Cap Opportunity In “Wet AMD”

The mid-cap biotech featured in today’s article is focused on retina therapeutics, including wet age-related macular degeneration (wet AMD), the total addressable market for which is estimated to be $10.4 billion globally by 2024. The company’s drug for wet AMD had proven to help with the disorder, and thus it seems highly likely it will be approved. So is this stock a buy? At least one well-known biotech investor thinks so! For more, CLICK HERE.